Clinical trial
Procarbazine and Isotretinoin in Treating Patients With Recurrent Primary…
NCT00003564 · M.D. Anderson Cancer Center, Other · Withdrawn
Key facts
| NCT number | NCT00003564 |
|---|---|
| Title | Procarbazine and Isotretinoin in Treating Patients With Recurrent Primary Malignant Gliomas |
| Official title | Phase III Randomized Evaluation of 13-Cis-Retinoic Acid (cRA) Plus Procarbazine Versus Procarbazine Alone in the Treatment of Patients With Recurrent Primary Malignant Gliomas |
| Lead sponsor | M.D. Anderson Cancer Center, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Withdrawn |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Brain and Central Nervous System Tumors |
| Intervention type | Drug |
| Interventions | Isotretinoin, Procarbazine Hydrochloride |
| Enrollment | 0 |
| First posted | Sep 13, 2004 |
| Last update posted | Feb 22, 2012 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: